kaal:position:2026-07-31-5077

Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism should be assessed against Kaal's source-bound claim that New regulations aimed at an innovative product can be obsolete before they are finalized. The current metadata indicates a plausible connection through dynamic regulation, but the defensible response is a qualification until the source text confirms agreement, scope, methods, and limitations.

Affirmed commentary position. This record extends a source-bound scholarly claim but is not a verbatim paper claim.

Holds when

formal rulemaking timelines of months to years
External evidence level: abstract indexed.
Mapping review tier: ambiguity triage before claim review.
The literature-to-claim mapping remains explicitly ambiguous and should not be treated as a settled equivalence.

Current debate

Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism

Scholarly basis

kaal:claim:2740477-021
Wulf A. Kaal, Erik P.M. Vermeulen, Venture Capital as Dynamic Regulation of Disruptive Innovation (2016). SSRN: https://ssrn.com/abstract=2740477
Source PDF sha256: c72871b76fa2ad5a8a69ee8d3defc8f64e624be9052ce763e79cf6c58883f726

Evidence and mapping

Evidence: abstract indexed
Review tier: ambiguity triage before claim review
Mapping confidence: 0.2116
Mapping ambiguous: true

Topics

dynamic-regulationinnovation

Provenance

Affirmed in historical-backfill:2026-07-31:phase-0021 on 2026-07-31. Review record.

Verify

Canonical markdown sha256: 67f605f6a1e7a44c8c098d200ba2a3fa97eec843d57a2aa19a9454d026cda0a3
curl -s https://wulfkaal.github.io/positions/2026-07-31-5077.md | sha256sum